Delcath announces inducement grants under nasdaq listing rule 5635(c)(4)

Queensbury, n.y.--(business wire)--delcath systems, inc. (nasdaq: dcth) (the “company” or “delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the company granted equity awards, previously approved by the company's compensation committee, as material inducements to eleven individuals whose employment commenced in march and april of 2025. the grants resulted in the right to purchase 111,000 shares of the company's.
NDAQ Ratings Summary
NDAQ Quant Ranking